GlobalData on MSN1 个月
Are dry powder inhalers the key to sustainable respiratory care?
GSK, leading the COPD market with its Trelegy Ellipta inhaler, is planning pivotal trials of Ventolin inhaler with an ...
pharmaphorum6 年
FDA approves expanded use for GSK's COPD triple therapy
The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...
Yahoo Finance1 个月
Are dry powder inhalers the key to sustainable respiratory care?
AstraZeneca’s Symbicort inhaler accounts for most of its inhalation ... Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo ...